Master Protocol of TCR-modified T Cell Therapy Targeting HLA-restricted KRAS Antigen Administered in Adult Patients With Metastatic or Locally Advanced PDAC

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(8 sites)

Denmark

Herlev and Gentofte University Hospital, Copenhagen

Germany

Charité Universitätsmedizin Berlin, Berlin

Technische Universitaet Dresden - Universitaetsklinikum Carl Gustav Carus, Dresden

Universitaetsklinikum Heidelberg, Heidelberg

University Hospital and Faculty of Medicine Eberhard Karls University Tübingen, Tübingen

Netherlands

Amsterdam UMC - VU Medical Center, Amsterdam

Radboud University Medical Center, Nijmegen

Sweden

Karolinska University Hospital, Stockholm